Baby KJ’s CRISPR Therapy: What It Cost—and What Comes Next

KJ Muldoon’s treatment showed that a gene editor could be designed for one child’s disease-causing variant and given while he was still an infant. It did not establish a price for doing that routinely—or prove that his disease has been cured. The distinction matters as researchers try to turn an extraordinary individual effort into a repeatable treatment model. 119

How much did Baby KJ’s therapy cost to manufacture?

There is no verified, itemized manufacturing cost for KJ’s treatment in the available sources. Reporting describes personalized treatments like his as costing hundreds of thousands of dollars to manufacture, but that broad figure should not be presented as the price of his doses. It also does not account for all the work involved in designing, testing and following a new therapy. 121

Cost estimates for a future, more efficient production system are a different question. Neither an estimate for a similar treatment nor funding for a manufacturing program establishes what KJ’s treatment cost. 212

How was the treatment developed?

KJ was born with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, a disorder that impairs the liver’s ability to clear nitrogen and can lead to dangerous ammonia buildup. Working with collaborators, researchers at Children’s Hospital of Philadelphia and Penn Medicine developed a CRISPR-derived base editor aimed at his particular genetic variant. The treatment used lipid nanoparticles to deliver the editor’s instructions to liver cells, where the team intended it to correct the variant. 171

Designing the editor was only part of the job. The team also had to carry out patient-specific safety and activity testing, prepare clinical-grade material and obtain expedited authorization for his individual treatment. The development effort took roughly six months; KJ received his first infusion in February 2025. 1420

What is known about KJ’s progress?

Children’s Hospital of Philadelphia reported that KJ had received three doses by April 2025, with no serious side effects reported at that point. In the early period after treatment, he tolerated more dietary protein and required less nitrogen-scavenging medication. Those are meaningful observations for a child whose condition had required a highly restricted diet, but they came from short-term follow-up. 2019

In its update marking one year since his first infusion, the hospital said KJ was walking and talking as he continued to grow. His longer-term response and safety still require follow-up. His clinicians have cautioned against calling the treatment a cure. 1719

Can a one-patient therapy become a treatment platform?

The proposed route to scale is to reuse as much as possible: an established editor and delivery approach, standardized production steps, and testing methods that do not have to be reinvented for every variant. Researchers would still need to show that each customized treatment is made consistently and has an acceptable safety profile. That is the difference between a reusable platform and assuming every new edit is automatically safe or effective. 16

ARPA-H’s THRIVE program is aimed at platforms for custom in-body genetic medicines, while its GIVE program supports made-to-order genetic-medicine manufacturing. ARPA-H has awarded $125 million across five groups for the RNA-based production effort. These are investments in future capacity, not evidence that an individual CRISPR treatment can already be produced or supplied affordably. 82

Regulation is evolving alongside manufacturing. The FDA has issued draft guidance for evaluating individualized treatments for extremely small patient populations, including an approach that considers whether a therapy plausibly addresses the disease’s cause. The draft does not waive the need for evidence of safety and effectiveness. Scientists involved in KJ’s treatment have also reported that manufacturing and quality-control requirements could make additional bespoke therapies prohibitively difficult or expensive to advance. 51311

The commercial path is uncertain, too: Aurora Therapeutics, a startup pursuing personalized gene-editing drugs, scrapped its lead program in August 2026. KJ’s case is therefore a proof of what a coordinated team could do for one patient—not yet a proven model for broad, affordable access. 101